Gardasil ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 4 |
49. 全身性エリテマトーデス
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01741012 (ClinicalTrials.gov) | January 2013 | 14/11/2012 | Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients | Phase I, Safety and Immunogenicity of Gardasil® in Systemic Lupus Erythematosus. | Systemic Lupus Erythematosus | Drug: Gardasil | Wayne State University | Merck Sharp & Dohme Corp. | Completed | 18 Years | 50 Years | Female | 37 | Phase 1 | United States |
| 2 | NCT01687192 (ClinicalTrials.gov) | October 2012 | 13/9/2012 | Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy. | Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy. | Transplantation;Systemic Lupus Erythematosus;Systemic Immune Disease | Biological: HPV prophylactic vaccine Gardasil | University Hospital, Bordeaux | NULL | Active, not recruiting | 9 Years | 18 Years | Female | 37 | Phase 2 | France |
| 3 | NCT00911521 (ClinicalTrials.gov) | October 2009 | 28/5/2009 | Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study | Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study | Systemic Lupus Erythematosus | Drug: human papillomavirus vaccination (Gardasil) | Tuen Mun Hospital | NULL | Completed | N/A | 35 Years | Female | 100 | Phase 4 | China |
| 4 | NCT00786409 (ClinicalTrials.gov) | November 2008 | 5/11/2008 | Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women | Immunogenicity and Safety of the Quadrivalent HPV Vaccine Gardasil in Female Systemic Lupus Erythematosus Patients Aged 9-26 | Systemic Lupus Erythematosus | Biological: Gardasil | University of Chicago | Merck Sharp & Dohme Corp. | Completed | 9 Years | 26 Years | Female | 27 | N/A | United States |